Experts Question Direct-to-Consumer Hormone Panels for Menopause

A pronounced rise in direct-to-consumer menopause services, including detailed hormone panels and compounded hormone preparations, is drawing scrutiny from medical experts who say such approaches often offer little clinical benefit, carry substantial cost, and risk commercial bias influencing care. At the same time, a broader debate continues over hormone therapy itself, with clinicians emphasizing careful risk–benefit assessment, individualized care, and ongoing research to improve personalization of treatment for midlife women.

Experts contend that menopause is a clinical diagnosis based on validated symptoms, and the routine use of hormone testing to guide treatment lacks a solid evidence base. Hormone panels are frequently marketed as essential for “individualizing” therapy, yet there is no clearly defined therapeutic window for menopausal hormone therapy, and many testing techniques fail to provide accurate or precise assessments of hormone levels. As a result, such tests do not reliably determine who will benefit from treatment, when menopause will end, or whether contraception should be discontinued. Longstanding clinical guidelines caution that testing adds little to...